Cargando…

Changes in the Body Composition and Nutritional Status after Long-term Rifaximin Therapy for Hyperammonemia in Japanese Patients with Hepatic Encephalopathy

OBJECTIVE: Rifaximin has become available for treating hyperammonemia in patients with hepatic encephalopathy. This study analyzed the changes in the body composition and nutritional status after long-term rifaximin therapy. METHODS: Twenty-one patients who underwent rifaximin therapy at 1,200 mg/da...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ishikawa, Toru, Endo, Saori, Imai, Michitaka, Azumi, Motoi, Nozawa, Yujiro, Sano, Tomoe, Iwanaga, Akito, Honma, Terasu, Yoshida, Toshiaki
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The Japanese Society of Internal Medicine 2020
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7662066/ https://www.ncbi.nlm.nih.gov/pubmed/33055469 http://dx.doi.org/10.2169/internalmedicine.5094-20

Ejemplares similares

Comparison of the efficacy of self-expandable metallic stents in colorectal obstructions caused by extracolonic malignancy and colorectal cancer
por: Sano, Tomoe, et al.
Publicado: (2021)

Prediction factors of tolvaptan effectiveness in patients with refractory ascites complicated with hepatocellular carcinoma
por: Imai, Michitaka, et al.
Publicado: (2020)

Clinical Usefulness of Transjugular Liver Biopsy in Patients With Hematological Diseases With Liver Dysfunction
por: Ishikawa, Toru, et al.
Publicado: (2021)

Eosinophilic esophagitis in Japanese patients: A mild and slow-progressing disorder
por: Sato, Hiroki, et al.
Publicado: (2018)

Evaluation of the branched-chain amino acid-to-tyrosine ratio prior to treatment as a prognostic predictor in patients with liver cirrhosis
por: Ishikawa, Toru, et al.
Publicado: (2017)

Successful Ombitasvir/Paritaprevir/Ritonavir Plus Ribavirin Retreatment for a Chronic Hepatitis C Genotype 2a Patient Who Relapsed after Sofosbuvir Plus Ribavirin Treatment
por: Ishikawa, Toru, et al.
Publicado: (2018)

Analysis of predictors after partial splenic embolization for thrombocytopenia with liver cirrhosis
por: Ishikawa, Toru, et al.
Publicado: (2022)

Cone beam versus conventional computed tomography angiography volume measurement in partial splenic embolization
por: Ishikawa, Toru, et al.
Publicado: (2019)

Efficacy and safety of repeated use of lusutrombopag prior to radiofrequency ablation in patients with recurrent hepatocellular carcinoma and thrombocytopenia
por: Ishikawa, Toru, et al.
Publicado: (2019)

Clinical efficacy of the highly sensitive hepatitis C virus RNA quantitative assay in patients with relapse following interferon-based therapy with second-generation direct-acting antivirals
por: ISHIKAWA, TORU, et al.
Publicado: (2016)

Improved survival with double platinum therapy transcatheter arterial infusion using cisplatin and transcatheter arterial chemoembolization using miriplatin for BCLC-B hepatocellular carcinoma
por: Ishikawa, Toru, et al.
Publicado: (2016)

Hemorrhagic Gastric Metastasis from Hepatocellular Carcinoma Successfully Treated Using Coil Embolization of the Left Gastric Artery
por: Imai, Michitaka, et al.
Publicado: (2019)

Efficacy of rifaximin against covert hepatic encephalopathy and hyperammonemia in Japanese patients
por: Nakai, Masato, et al.
Publicado: (2022)

Risk factors for difficult endoscopic hemostasis for colonic diverticular bleeding and efficacy and safety of transcatheter arterial embolization
por: Sano, Tomoe, et al.
Publicado: (2023)

Ascending Colon Varices Due to Left-sided Portal Hypertension
por: Ishikawa, Toru, et al.
Publicado: (2021)

Telaprevir-based triple therapy following partial splenic arterial embolization for chronic hepatitis C with thrombocytopenia can reduce carcinogenesis and improve hepatic function reserve
por: ISHIKAWA, TORU, et al.
Publicado: (2015)

Effects of body composition and liver function after long-term pemafibrate treatment on dyslipidemia-associated non-alcoholic fatty liver disease
por: Ishikawa, Toru, et al.
Publicado: (2023)

Predictive Factor of Local Recurrence after Balloon-Occluded TACE with Miriplatin (MPT) in Hepatocellular Carcinoma
por: Ishikawa, Toru, et al.
Publicado: (2014)

Rifaximin in the treatment of hepatic encephalopathy
por: Iadevaia, Maddalena Diana, et al.
Publicado: (2011)

Comparison of Ablation Volume Between Emprint(®) and Mimapro(®) Systems for Hepatocellular Carcinoma –A Preliminary Study
por: Ishikawa, Toru, et al.
Publicado: (2023)

Efficacy of long-term rifaximin treatment for hepatic encephalopathy in the Japanese
por: Nishida, Shinya, et al.
Publicado: (2019)

Rifaximin, Microbiota Biology, and Hepatic Encephalopathy
por: Peleman, Cedric, et al.
Publicado: (2016)

Methamphetamine-induced encephalopathy in the absence of hyperammonemia
por: Rabbany, Jessica M, et al.
Publicado: (2023)

Rifaximin as Treatment for Hepatic Encephalopathy: Some Considerations
por: Ridola, Lorenzo, et al.
Publicado: (2013)

Safety, efficacy, and patient acceptability of rifaximin for hepatic encephalopathy
por: Kimer, Nina, et al.
Publicado: (2014)

Cost-Effectiveness of Rifaximin Treatment in Patients with Hepatic Encephalopathy
por: Jesudian, Arun B., et al.
Publicado: (2020)

Postbariatric Surgery Hyperammonemia: A Rare Cause of Encephalopathy
por: Castineira, Janyll, et al.
Publicado: (2019)

Long-Term Efficacy and Safety of Rifaximin in Japanese Patients with Hepatic Encephalopathy: A Multicenter Retrospective Study
por: Kawaratani, Hideto, et al.
Publicado: (2022)

Modulation of the Metabiome by Rifaximin in Patients with Cirrhosis and Minimal Hepatic Encephalopathy
por: Bajaj, Jasmohan S., et al.
Publicado: (2013)

Rifaximin ameliorates intestinal inflammation in cirrhotic patients with hepatic encephalopathy
por: Tamai, Yasuyuki, et al.
Publicado: (2021)

Add-on Therapeutic Effects of Rifaximin on Treatment-resistant Hepatic Encephalopathy
por: Hayakawa, Yuka, et al.
Publicado: (2022)

A New-Onset Rash in the Setting of Rifaximin Treatment for Hepatic Encephalopathy
por: Fritz, Cassandra D.L., et al.
Publicado: (2014)

Metabolic syndrome is associated with poor response to rifaximin in minimal hepatic encephalopathy
por: Ballester, María-Pilar, et al.
Publicado: (2022)

Hyperammonemia Is Associated with Increasing Severity of Both Liver Cirrhosis and Hepatic Encephalopathy
por: Khan, Abidullah, et al.
Publicado: (2016)

Shunt occlusion prior to lenvatinib administration prevents hepatic encephalopathy and hyperammonemia
por: Kuwahara, Ai, et al.
Publicado: (2020)

Hyperammonemia and Hepatic Encephalopathy in Pediatric and Adult Liver Intensive Care Unit
por: Ocak, Ilhan, et al.
Publicado: (2023)

Comparison of Rifaximin and Lactulose for the Treatment of Hepatic Encephalopathy: A Prospective Randomized Study
por: Paik, Yong-Han, et al.
Publicado: (2005)

Rifaximin versus Nonabsorbable Disaccharides for the Treatment of Hepatic Encephalopathy: A Meta-Analysis
por: Wu, Dong, et al.
Publicado: (2013)

Systematic Review of the Economic Burden of Overt Hepatic Encephalopathy and Pharmacoeconomic Impact of Rifaximin
por: Neff, Guy, et al.
Publicado: (2018)

Rifaximin ameliorates hepatic encephalopathy and endotoxemia without affecting the gut microbiome diversity
por: Kaji, Kosuke, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_c14mc6q1dhhh1g2lj3ged249l8